HURA Form 4 reports acquisition/exercise transactions

Hoffman Robert E. reported acquisition or exercise transactions in a Form 4 filing for HURA.

Accepted by SEC EDGAR 02/17/2026 - 04:09 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Hoffman Robert E. reported acquisition or exercise transactions in a Form 4 filing for HURA. The filing lists transactions totaling 156,240 shares. Following the reported transactions, holdings were 156,240 shares.

Insider Trade Summary

Grant/Award: 156,240 shares

Grant/Award 1 txn

Insider Hoffman Robert E.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Options (Right to Buy)	156,240	$0.00	$0.00
Holding	Options (Right to Buy)	--	--	--

Holdings After Transaction: Options (Right to Buy) — 207,515 contracts for 51,275 underlying shares (Direct)

Holdings Before and After: Options (Right to Buy), 51,275 to 207,515 contracts (Direct)

Footnotes (2)

1. F1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
2. F2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did TuHURA Biosciences (HURA) report for Robert E. Hoffman?

TuHURA Biosciences reported that director Robert E. Hoffman received a grant of stock options. On February 12, 2026, he was awarded 156,240 options to buy common stock at a $1.29 exercise price under the 2024 Equity Incentive Plan.

How many stock options did Robert E. Hoffman receive in the latest TuHURA (HURA) Form 4 filing?

Robert E. Hoffman received 156,240 stock options in the most recent filing. These options are rights to buy TuHURA common shares at a $1.29 exercise price, subject to a three-year vesting schedule in equal annual installments beginning February 12, 2027.

What is the vesting schedule for Robert E. Hoffman’s new TuHURA (HURA) stock options?

The 156,240 options granted on February 12, 2026 vest over three years. One-third of the options become exercisable on each of the first, second, and third anniversaries of February 12, 2026, aligning with common multi-year director compensation structures.

What are the key terms of Robert E. Hoffman’s previously granted TuHURA (HURA) stock options?

The filing notes an earlier annual option grant of 51,275 options granted January 2, 2025. These options carry a $4.11 exercise price, vest one-third per year on each anniversary of January 2, 2025, and expire on January 2, 2035 if not exercised.

Does Robert E. Hoffman hold TuHURA (HURA) options directly or indirectly?

According to the Form 4, Robert E. Hoffman holds the reported options directly. Both the newly granted 156,240 options and the 51,275 previously granted options are listed with a direct ownership code, indicating direct beneficial ownership rather than through another entity.

Under which plan were Robert E. Hoffman’s TuHURA (HURA) options granted?

Both the new and prior option awards were granted under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. The February 12, 2026 grant and the January 2, 2025 grant are described as annual option grants provided as part of this equity compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Robert E.

(Last) (First) (Middle)

10500 UNIVERSITY CENTER DRIVE, SUITE 110

(Street)

TAMPA FL 33612

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TuHURA Biosciences, Inc./NV [ HURA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$1.29	02/12/2026(1)		A		156,240		(1)	02/12/2036	Common Stock	156,240	$0	156,240	D
Options (Right to Buy)	$4.11							(2)	01/02/2035	Common Stock	51,275		51,275	D

Explanation of Responses:

1. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.

2. Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.

	/s/ Robert E. Hoffman	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.